

February 19, 2024

To: All Concerned Parties

Company Name: Solasia Pharma K.K.  
Representative: Yoshihiro Arai, President & CEO  
(Code number: 4597, TSE Growth Section)  
Contact: Toshio Miyashita, CFO, Director  
Tel: 81-3-5843-8046

## Announcement Concerning Election of Five Board Directors and Two Audit & Supervisory Board Members

Solasia Pharma K.K. (hereinafter "the Company") hereby announces that at a Board of Directors meeting held today, it has resolved to submit a proposal to the 16th Annual General Meeting of Shareholders (the "Annual General Meeting of Shareholders ") to be held on March 22, 2024, for the appointment of all directors and two corporate auditors as follows.

### 1. Election of Five (5) Directors

The terms of office of all five (5) incumbent Board Directors of the Company will expire at the conclusion of this Annual General Meeting of Shareholders. Therefore, the Company proposes the election of five (5) Board Directors as reappointment of all Directors.

The candidates for Board Director are as follows;

No.	Name	Current position and responsibility in the Company
1	Yoshihiro Arai (Reelection)	President and Chief Executive Officer, Board Director
2	Toshio Miyashita (Reelection)	CFO and Head of Administration Division, Board Director
3	Stanley Lau (Reelection/Outside/Independent)	Board Director
4	Norikazu Eiki (Reelection/Outside/Independent)	Board Director
5	Jiro Mizukawa (Reelection/Outside/Independent)	Board Director

### 2. Election of Two (2) Auditors

The terms of office of two incumbent Audit & Supervisory Board Members, Makoto Matsuo and Yoshiyuki Yamakawa, will expire at the conclusion of this Annual General Meeting of Shareholders. Therefore, the Company proposes the election of two (2) Audit & Supervisory Board Members.

# Solasia

The candidates for Audit & Supervisory Board Members are as follows;

No.	Name	Current position and responsibility in the Company
1	Yoshiyuki Yamakawa (Reelection/Outside/Independent)	Audit & Supervisory Board Member
2	Nagisa Kawaida (Newly election/Outside/Independent)	—

## Candidate of New Auditor

Name Nagisa Kawaida

Date of Birth July 21, 1989

### Brief Background Description, Job Position, Concurrent Office

Dec. 2015 Registration of Attorney (Dai-Ichi Tokyo Bar Association)

Jan. 2016 Yodoyabashi & Yamagami Legal Professional Corporation

Apr. 2021 Partner (Current)

May. 2021 Researcher of Civil Affairs Bureau, Ministry of Justice (part-time)

Jul. 2021 Arbitrator and Compliance Committee Member of Women's Japan Basketball League (part-time)(Current)

### 3. Auditor to be resign (as of March 22, 2024)

Matsuo Makoto

### 4. New lineup of Directors and Auditors (March 22, 2024)

Position	New	Outside	Independent	Name
President and CEO				Yoshihiro Arai *
CFO, Director				Toshio Miyashita *
Director		○	○	Stanley Lau *
Director		○	○	Norikazu Eiki *
Director		○	○	Jiro Mizukawa *
Statutory Auditor		○	○	Susumu Araki
Auditor		○	○	Yoshiyuki Yamakawa *
Auditor	○	○	○	Nagisa Kawaida *

\* : Appointment is planned on approval at the 16th Annual General Shareholders Meeting.

# *Solasia*

Disclaimer:

The forward-looking statements, including earnings forecasts, contained in this press release are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Such statements should not be construed as representing commitments on the part of the Company. Please be aware that actual performance may differ for a variety of reasons. Major factors affecting the Company's actual performance include the economic conditions in which it operates, exchange rate fluctuations, the competitive situation and other factors. Information contained in this press release with regard to pharmaceuticals and medical devices (including products under development) is not provided for the purposes of advertising or medical advice.